Eastman Chemical: Specialty Focus Unlocks 14% Upside to Fair Value
By stockpickr AI | March 1, 2026 | 10 min read
Investment Summary
Eastman Chemical Company (EMR), a Materials sector player, appears slightly undervalued based on the DCF analysis, supported by its stable cash flows and strategic focus on specialty materials.
Investment Recommendation
Buy
Fair Value: $122.50
Current Price: $107.48
Upside/Downside: +14.0%
The DCF model produces an implied fair value of $122.50 per share, based on moderate growth and WACC assumptions, suggesting an upside potential of approximately 14.0% against the current price of $107.48. This undervaluation is primarily driven by strong, stable Free Cash Flow projections.
Key Metrics
- Market Cap: $12.93B
- P/E Ratio: 11.55x
- Forward P/E: 11.12x
- Revenue Growth (YoY): 0.98%
- Net Margin: 8.30%
- ROE: 17.21%
- Debt/Equity: 1.44
- Dividend Yield: 3.21%
Strengths
- Strong Free Cash Flow generation, averaging approximately $1.9B over the last three years, supporting dividends and debt repayment.
- High Return on Equity (ROE) of 17.21% as of the latest TTM, indicating efficient capital utilization.
- Strategic focus on high-value specialty materials and sustainable innovation (circular economy) provides long-term growth drivers.
- Attractive dividend yield of 3.21%, making it appealing for income-focused investors.
Risk Factors
- High leverage with a Debt-to-Equity ratio of 1.44, making it vulnerable to rising interest rates.
- Exposure to cyclical end-markets such as automotive and construction can compress margins during economic downturns.
- Operational headwinds from volatility in raw material costs and ongoing supply chain normalization.